William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer with prognosis, chemotherapy response, and other factors.
William M. Grady, MD, Clinical Research Division, Fred Hutchinson Cancer Research Center, GI Cancer Prevention Program, Seattle Cancer Care Alliance, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer (CRC) with prognosis, chemotherapy response, and other factors.
The group of investigators from this study sought to find molecular markers that could help determine treatment options, Grady explains. This area of research has grown in recent years with the continued focus on targeted therapies. The identification of molecular changes in colon cancer will help identify the most appropriate targeted therapy, resulting in optimal outcomes.
In the study, researchers examined gene expression data from 188 patients with CRC, followed by validation through the examination of 543 patients. Overall, 3 intrinsic subtypes of CRC were identified based on the biology of the tumors. Moreover, these subtypes were each associated with varying outcomes and treatment sensitivity (Find out more, view the study).
Grady believes this trial will usher in a new era for molecular diagnostics in CRC. Furthermore, he states, it will soon be possible to examine molecular changes in CRC overtime and personalize treatment based on these changes.